Cosentyx affects what cell?

What cell does Cosentyx (secukinumab) target?

Cosentyx affects a specific immune signaling pathway by blocking interleukin-17A (IL-17A), a cytokine made by inflammatory immune cells, especially Th17 (T helper) cells. By neutralizing IL-17A, Cosentyx reduces inflammation driven by cells that rely on IL-17A signaling. [1]

Is it the same “cell type” as the ones causing symptoms?

Cosentyx does not bind to only one cell type like a “cell target” drug (for example, it does not directly target a single cell surface marker on one cell class). Instead, it targets IL-17A, which is produced by immune cells (notably Th17 cells) and drives inflammatory responses in tissues involved in psoriasis and related conditions. [1]

Where does IL-17A signaling show up in disease?

IL-17A signaling contributes to the inflammatory process seen in plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Blocking IL-17A interrupts that inflammatory cascade downstream from IL-17A-producing immune cells. [1]

Source

[1] https://www.drugs.com/cosentyx.html